ISSN: 1040-8746

Journal Home

Journal Guideline

Current Opinion in Oncology Q2 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Opinion in Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 104. It has an SJR impact factor of 0,99 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,99.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q2) Oncology (Q2)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,99

SJR Impact factor

104

H Index

85

Total Docs (Last Year)

290

Total Docs (3 years)

4473

Total Refs

919

Total Cites (3 years)

267

Citable Docs (3 years)

2.68

Cites/Doc (2 years)

52.62

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2

Compare this journals

Aims and Scope

Best articles by citations

Fluorescence resonance energy transfer in the study of cancer pathways

Statistical methods applied to omics data

Emerging new anticancer therapies in 2013

Mapping genetic alterations in tumors with single nucleotide polymorphisms

Chronic myelogenous leukemia

Giant cell tumour of bone

List of journals scanned

Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice

Update: gastric MALT lymphoma

Of art and science

The role of surgical resection in patients with brain metastases

Ocular manifestations of central nervous system lymphoma

SHOW MORE ARTICLES

Surveillance recommendations for patients with germline TP53 mutations

New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia

Treatment of patients with early epithelial ovarian cancer

Acute progranulocytic leukemia

Recent developments in supporting adolescent and young adult siblings of cancer patients

Costimulatory approaches to adoptive immunotherapy

Cellular adoptive immunotherapy after allogeneic stem cell transplantation

Targeting the molecular target of rapamycin (mTOR)

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

Recent advances in pediatric acute lymphoblastic and myeloid leukemia

Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment

Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha